The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Associations between [ 18 F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample
Open accessAbstract
Objective To assess the relationships between fluid and imaging biomarkers of tau pathology and compare their diagnostic utility in a clinically heterogeneous sample. Methods Fifty-three patients (28 with clinical Alzheimer disease [AD] and 25 with non-AD clinical neurodegenerative diagnoses) underwent β-amyloid (Aβ) and tau ([18F]AV1451) PET and lumbar puncture. CSF biomarkers (Aβ42, total tau [t-tau], and phosphorylated tau [p-tau]) were measured by multianalyte immunoassay (AlzBio3). Receiver operator characteristic analyses were performed to compare discrimination of Aβ-positive AD from non-AD conditions across biomarkers. Correlations between CSF biomarkers and PET standardized uptake value ratios (SUVR) were assessed using skipped Pearson correlation coefficients. Voxelwise analyses were run to assess regional CSF–PET associations. Results [18F]AV1451-PET cortical SUVR and p-tau showed excellent discrimination between Aβ-positive AD and non-AD conditions (area under the curve 0.92–0.94; ≤0.83 for other CSF measures), and reached 83% classification agreement. In the full sample, cortical [18F]AV1451 was associated with all CSF biomarkers, most strongly with p-tau (r = 0.75 vs 0.57 for t-tau and −0.49 for Aβ42). When restricted to Aβ-positive patients with AD, [18F]AV1451 SUVR correlated modestly with p-tau and t-tau (both r = 0.46) but not Aβ42 (r = 0.02). On voxelwise analysis, [18F]AV1451 correlated with CSF p-tau in temporoparietal cortices and with t-tau in medial prefrontal regions. Within AD, Mini-Mental State Examination scores were associated with [18F]AV1451-PET, but not CSF biomarkers. Conclusion [18F]AV1451-PET and CSF p-tau had comparable value for differential diagnosis. Correlations were robust in a heterogeneous clinical group but attenuated (although significant) in AD, suggesting that fluid and imaging biomarkers capture different aspects of tau pathology. Classification of evidence This study provides Class III evidence that, in a clinical sample of patients with a variety of suspected neurodegenerative diseases, both CSF p-tau and [18F]AV1451 distinguish AD from non-AD conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these biomarkers remain at normal concentrations in other neurodegenerative disorders with substantial neurodegeneration,8, 9, 10 and also those with tau pathology.11, 12, 13”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 9×
“Mini-Mental State Examination scores were only associated with [18F]AV1451 PET biomarkers for AD.”
BackgroundInfluentialSelf-citationLitvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Criteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904
Self-citationEarly clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807
Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605
An autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD
Rabinovici, G. D., Rosen, H. J., Alkalay, A., Kornak, J., Furst, A. J., Agarwal, N., Mormino, E. C., O'Neil, J. P., Janabi, M., Karydas, A., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823b9c5e · Cited by 318
Self-citationAtrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease
Ossenkoppele, R., Cohn‐Sheehy, B. I., La Joie, R., Vogel, J. W., Möller, C., Lehmann, M., van Berckel, B. N. M., Seeley, W. W., Pijnenburg, Y. A., Gorno‐Tempini, M. L., et al. (2015) · Human Brain Mapping · doi:10.1002/hbm.22927 · Cited by 243 · cited 1×
“This was done by comparing each patient’s warped SUVR image to an independent group of 53 PiB-negative cognitively normal individuals using a W-score procedure adjusting for age.(22,23) Abnormal voxels were defined as those with W > 2 (corresponding to the 97.”
MethodSelf-citationToledo, J. B., Bjerke, M., Da, X., Landau, S. M., Foster, N. L., Jagust, W., Jack, C., Weiner, M., Davatzikos, C., Shaw, L. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4829 · Cited by 88
Self-citation
Research works printed but not linked: 29
- 10.1016/j.jalz.2011.03.005 · DOI · Paper page
- 10.1016/S1474-4422(14)70090-0 · DOI · Paper page
- 10.1212/WNL.0000000000002923 · DOI · Paper page
- 10.1016/j.tips.2015.03.002 · DOI · Paper page
- 10.1002/ana.20730 · DOI · Paper page
- 10.1093/brain/aww027 · DOI · Paper page
- 10.1002/ana.24517 · DOI · Paper page
- 10.1212/WNL.0000000000003050 · DOI · Paper page
- 10.1093/brain/aww139 · DOI · Paper page
- 10.1212/WNL.0b013e31821103e6 · DOI · Paper page
- 10.1093/brain/awr179 · DOI · Paper page
- 10.1073/pnas.200033797 · DOI
- 10.1016/j.neuroimage.2017.05.058 · DOI · Paper page
- 10.1093/brain/awv112 · DOI · Paper page
- 10.1523/JNEUROSCI.2170-12.2012 · DOI · Paper page
- Pernet CR, Wilcox R, Rousselet GA. Robust correlation analyses: false positive and power validation using a new open source MATLAB toolbox. Front Psychol 2012;3:606.
- 10.3389/fninf.2016.00020 · DOI
- 10.1002/ana.23908 · DOI · Paper page
- 10.3233/JAD-132561 · DOI
- 10.1016/j.neurobiolaging.2016.03.025 · DOI · Paper page
- 10.1016/j.jalz.2014.03.006 · DOI · Paper page
- 10.1002/ana.24885 · DOI · Paper page
- 10.1007/s00702-014-1226-y · DOI
- 10.1007/s00401-013-1151-4 · DOI · Paper page
- 10.1186/1750-1326-9-22 · DOI
- 10.1126/scitranslmed.3007901 · DOI · Paper page
- 10.3233/JAD-2011-101911 · DOI
- 10.1212/WNL.52.6.1158 · DOI · Paper page
- Mattsson N, Carrillo MC, Dean RA, et al. Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimers Dement 2015;1:412–419.
Cited by
Sorted by citations
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Self-citationthe Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Self-citationLa Joie, R., Visani, A. V., Baker, S. L., Brown, J. A., Bourakova, V., Cha, J., Chaudhary, K., Edwards, L., Iaccarino, L., Janabi, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5732 · Cited by 612
Self-citationOssenkoppele, R., Rabinovici, G. D., Smith, R., Cho, H., Schöll, M., Strandberg, O., Palmqvist, S., Mattsson, N., Janelidze, S., Santillo, A., et al. (2018) · JAMA · doi:10.1001/jama.2018.12917 · Cited by 472
Self-citation
Metadata
- Authors
- La Joie, R., Bejanin, A., Fagan, A. M., Ayakta, N., Baker, S. L., Bourakova, V., Boxer, A. L., Cha, J., Karydas, A., Jerome, G., Maass, A., Mensing, A., Miller, Z. A., O'Neil, J. P., Pham, J., Rosen, H. J., Tsai, R., Visani, A. V., Miller, B. L., Jagust, W. J., & Rabinovici, G. D.
- Affiliations
- From the Memory and Aging Center (R.L.J., A.B., N.A., V.B., A.L.B., J.C., A.K., A.M., Z.A.M., J.P., H.J.R., R.T., A.V., B.L.M., G.D.R.), University of California San Francisco; Knight Alzheimer's Disease Research Center (A.M.F., G.J.), Department of Neurology (A.M.F., G.J.), and The Hope Center for Neurological Disorders (A.M.F., G.J.), Washington University in St. Louis, MO; Molecular Biophysics and Integrated Bioimaging Division (S.L.B., J.P.O., W.J.J.), Lawrence Berkeley National Laboratory,...
- Lawrence Berkeley National Laboratory (US)
- ORCID
- Venue
- Neurology
- Published
- 2018-01-23
- Volume
- 90
- Issue
- 4
- Pages
- e282-e290
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC5798657
- OpenAlex
- W2781092115
- Cited by
- 141
- References
- 10
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 13 · 2023: 14 · 2022: 24 · 2021: 28 · 2020: 28 · 2019: 17 · 2018: 7
- FWCI
- 11.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Alzheimer's Association (P50 AG023501, 443577, AARF-16-443577, 16-443577)
- National Institute on Aging (R01AG045611, K23AG048291, R01AG032306, P50AG005681, P01AG003991, K24AG045333, R01AG038791, P01AG019724, R01AG034570, P01AG026276, P50AG023501)
- National Institute of Neurological Disorders and Stroke (U54NS092089)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- 18F-AV-1451, tau PET, tau pathology, phosphorylated tau, cerebrospinal fluid biomarkers, Alzheimer's disease, differential diagnosis, amyloid-beta, total tau, neurodegenerative diseases, diagnostic accuracy, cognitive impairment, temporoparietal cortex
- MeSH terms
- Aged, Brain, Carbolines, Cross-Sectional Studies, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Peptide Fragments, Phosphorylation, Retrospective Studies, ROC Curve, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Radiopharmaceuticals, Area Under Curve, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
